A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of MRG-201 Following Local Intradermal Injection in Normal Healthy Volunteers

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of MRG-201 Following Local Intradermal Injection in Normal Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs MRG 201 (Primary)
  • Indications Scleroderma
  • Focus Adverse reactions; First in man
  • Sponsors miRagen Therapeutics
  • Most Recent Events

    • 11 Aug 2017 Acccording to a miRagen Therapeutics media release, the Company plans to present final clinical trial results at a scientific conference before the end of this year (2H 2017).
    • 05 Jul 2017 Status changed from recruiting to completed.
    • 10 May 2017 Acccording to a miRagen Therapeutics media release, the company expects to complete the trial in the second quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top